Sequel Med Tech and Arecor Partner to Advance Ultra-Concentrated Insulin Delivery

Sequel Med Tech, a leading medical device manufacturer, has announced a collaboration with Arecor Therapeutics to develop an innovative insulin delivery system. The partnership aims to combine Sequel's twiist insulin pump with Arecor's ultra-concentrated AT278 insulin, potentially revolutionizing diabetes management for patients requiring high daily doses.

Ultra-Concentrated Insulin Meets Advanced Pump Technology

Arecor's AT278 insulin boasts a concentration of 500 units per milliliter, approximately five times more potent than standard insulin formulations currently on the market. This high concentration could offer significant benefits to patients, including longer wear times for insulin pumps and the possibility of smaller, more discreet wearable devices.

Sequel's twiist insulin pump, which received FDA clearance in 2024, utilizes innovative sound wave technology to accurately measure microdoses of insulin. This precision allows for quick detection of blockages and smoother insulin delivery over time, making it an ideal candidate for dispensing high-concentration formulations like AT278.

Clinical Trial Plans and Financial Commitment

The collaboration between Sequel Med Tech and Arecor Therapeutics includes a joint investment of up to $1.3 million each to prepare for a pivotal Phase 2 study. The trial, scheduled for the second half of next year, will involve patients with both Type 1 and Type 2 diabetes.

Sarah Howell, CEO of Arecor, expressed enthusiasm for the partnership, stating, "We are proud to be bringing devices and therapeutics together in a collaboration which addresses a real unmet need in a high-value market, helping people with diabetes better manage their blood glucose whilst significantly lowering the daily burden of disease management."

Future Prospects and Market Potential

The combination of AT278 and the twiist pump has the potential to expand the benefits of automated insulin delivery (AID) systems to a broader range of patients. Alan Lotvin, CEO of Sequel, highlighted this potential, saying, "Together, this combination has the potential to expand the benefits of AID to all individuals on intensive insulin therapy and provide additional options for [people with diabetes], helping them achieve tighter glucose control and improved outcomes."

While initial efforts are focused on the upcoming clinical trial, the partnership also includes long-term plans for commercializing the combined system outside the United States. This global outlook underscores the potential impact of this innovative approach to insulin delivery on the diabetes care market worldwide.